A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Recruiting · NCT06566170
Conditions: Alzheimer Disease
At a glance
- Research payments reported, 2025
- $8.1M
- U.S. investigators named
- 28
- Sites paid
- 18
- Planned or actual enrollment
- 6,250
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Donanemab (drug), Usual Care (drug)
- Dates
- Started 2024-10-07; completion 2031-05
- Results posted
- Not yet
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $8.1M in research payments for this study in 2025 (51 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Belinda A. Savage-edwards, M.D. Specialist · Huntsville, AL
- Hemant K. Pandey, MD Neurology · Chandler, AZ
- Wei Mi, M.D. Neurology · Mission Hills, CA
- Haeryong Oh, M.D. Neurology · Long Beach, CA
- Sanjeev Zutshi, M.D. Internal Medicine · Port Charlotte, FL
- Aamer Habib, MD Neurology · Champaign, IL
- Tegan Mccormick Internal Medicine · Champaign, IL
- Jonathan D. Condit, DO Family Medicine · Muncie, IN
- George M. Cornett, M.D. Internal Medicine · Franklin, IN
- Kristi K. George, MD Neurology · Indianapolis, IN
- Talessa Powell, MD Family Medicine · Greenfield, IN
- Christopher M. Wilson, MD Neurology · Avon, IN
- Geri K. Hart, MD Family Medicine · Hutchinson, KS
- Mrinalini Prasanna, MD Student in an Organized Health Care Education/Training Program · Boston, MA
- Ehab Sorial, M.D. Internal Medicine · Fall River, MA
- Anelyssa Cysne Frota D' Abreu, MD Neurology · Grand Rapids, MI
- Pamela L. Ralls, M.D. Family Medicine · Carrollton, MO
- Melissa R. Champe - Seagle, M.D. Internal Medicine · Mocksville, NC
- Craig D. Dubois, M.D. Neurology · Mooresville, NC
- Brian R. Webster, M.D. Internal Medicine · Wilmington, NC
- David Podwall, M.D. Neurology · Lake Success, NY
- Martin Sadowski, M.D. Neurology · New York, NY
- Ryan S. Drake, DO Neurology · Canton, OH
- Meghan C. Riddle, M.D. Psychiatry · Providence, RI
- Gretchen L. Crook, MD Family Medicine · Austin, TX
- Jonathan A. Garza, M.D. Neurology · Houston, TX
- David O. Lindstrom, MD Family Medicine · Everett, WA
- Braden T. Nago, MD Neurology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Josephson Wallack Munshower Neurology $2.6M
- Neuroscience Research Center LLC $1.4M
- University of Virginia Medical Center, VA $1.0M
- Mdfirst Research Chandler LLC $1.0M
- Innovo Research $558,293
- American Health Network of in LLC $541,570
- Butler Hospital, RI $364,027
- Kelsey Research Foundation $281,515
- Collaborative Care Services, Inc. $241,034
- New York University $48,963
- Rehabilitation & Neurological Services, Ll $10,556
- Neurological Associates of Long Island PC $5,500
- Elligo Health Research Inc $4,466
- Neccr Prima Care Research LLC $1,507
- Christie Clinic, LLC $384
- Piedmont Healthcare, Inc $110
- Piedmont Hospital, Inc, GA $110
- Austin Regional Clinic $99
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.